Genital Secretion HIV RNA Shedding in HIV-Positive Patients on Ritonavir-Boosted Protease Inhibitor Monotherapy or Standard Combination ART: A Cross-Sectional Sub-Study from the PIVOT Trial
| Autor: | Vincent Lee, Wolfgang Stöhr, David Dunn, Alejandro Arenas-Pinto, Bridget Ferns, Eleni Nastouli, Nicholas J. Beeching, Rebecca Wiggins, Nicholas I. Paton, Laura Else, Zoe Warwick, Amanda Clarke, Charles J.N. Lacey, Saye Khoo |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Male
Human immunodeficiency virus (HIV) HIV Infections medicine.disease_cause Semen Antiretroviral Therapy Highly Active Humans Medicine Pharmacology (medical) Sex organ In patient Genitalia Pharmacology Ritonavir business.industry HIV Protease Inhibitors Middle Aged Virology Virus Shedding Cross-Sectional Studies Infectious Diseases Genital tract Vagina RNA Viral Female Genital secretion business medicine.drug |
| Zdroj: | Antiviral Therapy. 25:55-59 |
| ISSN: | 2040-2058 1359-6535 |
| Popis: | Background Protease inhibitors (PI) have relatively low penetration into the genital tract, raising concerns about the potential for genital HIV RNA shedding in patients taking PI-based regimens, particularly PI monotherapy (PI-mono). Methods We measured HIV RNA and PI drug concentrations in samples of semen, cervicovaginal and rectal mucosa secretions, and plasma in patients after 48–96 weeks on PI-mono or standard triple therapy. Results A total of 85 participants were recruited. Of the 43 participants on PI-mono (70% on darunavir [DRV]/ ritonavir [r]), 3 had detectable virus in semen or vaginal secretions (all below quantification limit), and none in rectal mucosa or plasma. Among those taking triple therapy, five had detectable virus in semen or vaginal secretions (HIV RNA >50 copies/ml in one), none in rectal mucosa and one in plasma. The median (IQR) concentration of DRV and atazanavir in semen (659.7 [339–1,089] and 128.8 [63–368] ng/ml, respectively) and cervico-vaginal samples (2,768 [312–7,879] and 1,836 [359–3,314] ng/ml, respectively) exceeded their protein adjusted median inhibition concentration (MIC50). DRV concentration in rectal secretions showed higher variability compared with concentration in the other sites, with particularly high rectal secretion/blood ratios (median 8.4, IQR 2.6–68.7:1). Conclusions We found no substantive evidence of HIV shedding in patients taking PI-mono, suggesting that PIs provide adequate control of virus in the genital compartment and are unlikely to lead to ongoing sexual transmission. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|